Drug intelligence / Profile preview

cisplatin + etoposide + vindesine

Development stage: Phase 3
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

Cisplatin + etoposide + vindesine is a combination chemotherapy regimen used primarily in the treatment of advanced non-small cell lung cancer (NSCLC). Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks and prevents cell division. Vindesine is a vinca alkaloid that inhibits microtubule assembly, disrupting mitosis. The combination aims to exploit synergistic cytotoxic effects on rapidly dividing tumor cells. Clinical studies have shown moderate response rates and acceptable toxicity profiles for this regimen in NSCLC patients[1][2].

Other names: PVPVD

Targets

DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cisplatin + etoposide + vindesine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + etoposide + vindesine.